EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions

Ibrahim Aldoss iD, Michelle Afkhami, Dongyun Yang, Zhaohui Gu, Sally Mokhtari, Shilpa Shahani, Hoda Pourhassan iD, Vaibhav Agrawal iD, Paul Koller, Shukaib Arslan iD, Vanina Tomasian, Monzr M Al Malki iD und 18 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Ibrahim Aldoss und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duar…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation, Antibodies, Bispecific. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Philadelphia (Ph)‐like acute lymphoblastic leukemia (ALL) is associated with a poor response to standard chemotherapy. However, outcomes with novel antibody and cellular therapies in relapsed/refractory (r/r) Ph‐like ALL are largely unknown. We conducted a single‐center retrospective analysis of adult patients ( n = 96) with r/r B‐ALL and fusions associated with Ph‐like who received novel salvage therapies. Patients were treated with 149 individual novel regimens (blinatumomab = 83, inotuzumab ozogamicin [InO] = 36, and CD19CAR T cells = 30). The median age at first novel salvage therapy was 36 years (range; 18–71). Ph‐like fusions were IGH::CRLF2 ( n = 48), P2RY8::CRLF2 ( n = 26), JAK 2 ( n = 9), ABL‐class ( n = 8), EPOR::IGH ( n = 4) and ETV6::NTRK2 ( n = 1). CD19CAR T cells were administered later in the course of therapy compared to blinatumomab and InO ( p < .001) and more frequently in recipients who relapsed after allogeneic hematopoietic cell transplantation (alloHCT) ( p = .002). Blinatumomab was administered at an older age compared to InO and CAR T‐cells ( p = .004). The complete remission (CR)/CR with incomplete hematologic recovery (CRi) rates were 63%, 72%, and 90% following blinatumomab, InO and CD19CAR, respectively, among which 50%, 50%, and 44% of responders underwent consolidation with alloHCT, respectively. In multivariable analysis, the type of novel therapy ( p = .044) and pretreatment marrow blasts ( p = .006) predicted the CR/CRi rate, while the Ph‐like fusion subtype ( p = .016), pretreatment marrow blasts ( p = .022) and post‐response consolidation with alloHCT ( p < .001) influenced event‐free survival. In conclusion, novel therapies are effective in inducing high remission rates in patients with r/r Ph‐like ALL and successfully transitioning the responders to alloHCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationAntibodies, BispecificAdultHumansRetrospective StudiesInotuzumab OzogamicinRemission Induction

Substanzen

Inotuzumab OzogamicinAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA.
  • Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
  • Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA.
  • Department of Clinical and Translational Project Development, City of Hope National Medical Center, Duarte, California, USA.
  • Department of Pediatrics, City of Hope National Medical Center, Duarte, California, USA.

ORCID-Profile: Ibrahim Aldoss, Hoda Pourhassan, Vaibhav Agrawal, Shukaib Arslan, Monzr M Al Malki, Amandeep Salhotra, Haris Ali, Brian Ball, Salman Otoukesh, Idoroenyi Amanam, Ryotaro Nakamura, Vinod Pullarkat

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Aldoss, I., Afkhami, M., Yang, D., Gu, Z., Mokhtari, S., Shahani, S., Pourhassan, H., Agrawal, V., Koller, P., Arslan, S., Tomasian, V., Al Malki, M. M., Artz, A., Salhotra, A., Ali, H., Aribi, A., Sandhu, K. S., Ball, B., Otoukesh, S., …, & Pullarkat, V. (2023). High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions. American Journal of Hematology. https://doi.org/10.1002/ajh.26908

Vancouver

Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, et al. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions. American Journal of Hematology. 2023. doi:10.1002/ajh.26908

BibTeX
@article{Aldoss2023,
  author = {Aldoss, Ibrahim and Afkhami, Michelle and Yang, Dongyun and Gu, Zhaohui and Mokhtari, Sally and Shahani, Shilpa and Pourhassan, Hoda and Agrawal, Vaibhav and Koller, Paul and Arslan, Shukaib and Tomasian, Vanina and Al Malki, Monzr M and Artz, Andrew and Salhotra, Amandeep and Ali, Haris and Aribi, Ahmed and Sandhu, Karamjeet S and Ball, Brian and Otoukesh, Salman and Amanam, Idoroenyi and Becker, Pamela S and Stewart, Forrest M and Curtin, Peter and Smith, Eileen and Telatar, Milhan and Stein, Anthony S and Marcucci, Guido and Forman, Stephen J and Nakamura, Ryotaro and Pullarkat, Vinod},
  title = {High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26908}
}
Kostenlos starten →